This Quarterly Report should be read in conjunction with the risk factors included in Item 1A. Risk Factors in our Annual Report. We are not aware of any material changes to the risk factors disclosed in our Annual Report except for the risk factor set forth below. There has been recent dilution and there may continue to be additional future dilution of our common stock, including as a result of the Company’s ATM Program (as defined below), which could adversely affect the market price of shares of our common stock. On May 5, 2026, we entered into a sales agreement with Roth Capital Partners, LLC (the “Agent”) (the “Sales Agreement”) pursuant to which we may issue and sell, from time to time, up to $150.0 million of shares of our common stock, through or to the Agent, acting as agent or principal, under the Sales Agreement in at-the-market transactions (the “ATM Program”). From May 5, 2026 to the date of this Quarterly Report, the outstanding shares of our common stock have increased by 32,292,485 shares as a result of sales pursuant to the ATM Program. We may issue additional shares of common stock to raise cash to bolster our liquidity, to repay, refinance, redeem or exchange indebtedness (including expenses, accrued interest, and premium, if any), for working capital, to finance strategic initiatives and future acquisitions, or for other purposes. Additional issuances will dilute the ownership interest of our common stockholders. Investors who purchase shares in our ATM Program at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience declines in the value of their shares as a result of share sales made at prices lower than the prices they paid. In addition, future issuances of common stock, including through our ATM Program, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our common stock or other equity-related securities would have on the market price of our common stock.